Pancreatic islet β-cells secrete insulin in a biphasic pattern consisting of a robust first phase insulin secretion (F-PIS) (5-10min) triggered by ATPsensitive K + channel (K ATP )-dependent Ca 2+ influx, followed by longer lasting low level second phase insulin secretion (S-PIS) (1) . F-PIS arises from a small subset of insulin vesicles docked at the plasma membrane and primed for ready release-the readily releasable pool (RRP). S-PIS is restricted by the rate of mobilization and subsequent priming of insulin vesicles to refill the depleted RRP (2) . This biphasic insulin release pattern is perturbed in patients with type-2 diabetes, resulting in abolished F-PIS and a blunted S-PIS(3). Glucagon-like peptide-1 (GLP-1) has been shown to partially bypass these insulin secretory defects of type-2 diabetes through cAMP signaling pathways (4) , but the molecular mechanism by which GLP-1 restores insulin exocytotic defects in diabetes remains unclear.
SNARE (soluble N-ethylmaleimidesensitive factor attachment protein receptor) proteins shown to mediate neuroexocytosis(5) also mediate insulin exocytosis (6) . Munc13 proteins serve priming functions by assisting in the unfolding of SNARE protein syntaxin to its open conformation, which enables SNARE complex formation (7;8) . Munc13 isoforms contain diacylglycerol (DAG)-binding C1 domain (7) , which upon activation by DAG promotes their translocation from cytosol to the plasma membrane (9) and is required to achieve the full priming activity(7;9;10). Munc13 priming actions lead to increase in size and release probability of the RRP in neurons and β-cells (10;11) . Using Munc13-1 deficient mouse models, Munc13-1 was indeed shown to be the major DAG receptor responsible potentiation of neurotransmitter (10) and insulin secretion (9;11;12) . Remarkably, heterozygous Munc13-1 knockout mice (Munc13-1 +/-) exhibited impaired F-PIS and S-PIS causing glucose intolerance, and mimicking type-2 diabetes(11). The reduction of islet level of Munc13-1 in Munc13-1 +/-mice is similar to that in type-2 diabetic patients and rodent models (9;13) .
cAMP/GLP-1 potentiation of insulin exocytosis has been attributed to an increase in initial size and refilling of the RRP of insulin vesicles (14;15) . Whereas molecular substrates acted upon by cAMP stimulation in more proximal steps of β-cell excitation-secretion coupling (i.e. ion channels gating, Ca 2+ release) are wellstudied, cAMP substrates at the level of exocytosis are just now being elucidated (16) (17) (18) (19) . cAMP/PKA activation phosphorylates a number of exocytotic proteins involved in synaptic(20;21) and neuroendocrine secretion (18) , the most important of which is Rab3A-interacting molecules (Rim). We hypothesized that Munc13-1 interactions with Rim proteins mediate insulin exocytosis, based on the following observations: 1) Rim, enriched in presynaptic active zones (22) as is Munc13-1 (23) , is essential for normal probability of neuroexocytosis (24) .
2) PKA phosphorylation of Rim is required for Rim-mediated long-term synaptic plasticity (21) . 3) Rim binds Munc13-1 at its N-terminal domain via its Zn 2+ finger region (25;26) , which regulates presynaptic recruitment (27) and priming activity (25;26) of Munc13-1. 4) Munc13-1 levels are reduced in Rim-deficient brain (24) . Another cAMP exocytic substrate is guanine exchange proteins (Epacs, also called cAMP-guanine exchange factorsGEFs) (28) . In islet β-cells, Epac, via PKAindependent mechanisms(18), modulates some proximal steps of insulin secretion, including ion channels (K ATP , ClC3-channels) (29;30) and Ca 2+ release (17) . Epac involvement in more distal steps of insulin exocytosis is via its direct interactions with Rim (18) .
The current body of work is compatible with our hypothesis postulating the interaction of Munc13-1 with PKA (via Rim) and Epacdependent signaling in priming insulin exocytosis. Munc13-1 +/-mice exhibit abnormal biphasic insulin secretory response mimicking type 2 diabetes, with defects in priming and refilling of a releasable pool of insulin secretory vesicles (11;12) . This model presents a unique opportunity to examine the ability of cAMP stimulation to rescue these exocytotic defects, and dissect the independent contribution to this cAMP rescue by Epac or PKA. Remarkably, we find that while Epac's ability to potentiate insulin exocytosis is restricted by the abundance of islet Munc13-1, PKA signaling, in part via Rim2, is more efficacious in overcoming Munc13-1 deficiency-induced exocytotic defects in priming and refilling of a releasable pool of insulin vesicles to restore insulin secretion.
Research Design and Methods

Animals-PCR
and DNA electrophoresis were performed to determine the genotypes of the Munc13-1 +/+ wild-type and Munc13-1 +/-knockout mice (10) . All experimental procedures are approved by the University of Toronto.
Immunoblotting--Isolated islets were solubilized in sample buffer (2% SDS) and loaded and separated on SDS-PAGE (Epac2, 30µg of protein, 6% PAGE; Rim2α, 30µg of protein, 10% PAGE; β-actin, 30µg of protein, 10% PAGE). Separated proteins were identified with primary antibodies [goat anti-Epac2 (Santa Cruz Biotechnology, Santa Cruz, CA), 1:100; rabbit anti-Rim2α, 1:1000 (Synaptic Systems, Gottingen, Germany); monoclonal mouse anti-β-actin, 1:20,000 (Sigma, St. Louis, MO)] and appropriate peroxidaselabeled second antibodies, visualized by chemiluminescence (Pierce).
Islet perifusion secretory assay and cAMP measurements-Mouse pancreatic islets were isolated as described previously (11) , allowed to recover for at least 2h (11mmol/l glucose), and then cultured in 2.8mmol/l glucose (1h). Batches of ~25 islets were placed in perifusion chambers with a capacity of ~1.3ml at 37°C and perifused at a flow rate of ~1ml/min with a KrebsRinger bicarbonate buffer (10mmol/l HEPES or KRBH; pH 7.4. 0.07% BSA). Islets were equilibrated for 30min in KRBH (2.8mmol/l glucose) before being subjected to the following stimulation protocols: 1) 2.8mmol/l glucose for 10min followed by 16.7mmol/l glucose plus 10nmol/l GLP-1 (7-36)-amide (Bachem, Torrance, CA) for 40min. 2) 2.8mmol/l glucose for 10min, then 16.7mmol/l glucose for 40min, and a final 16.7mmol/l glucose plus 10nmol/l GLP-1 for 40min.
3) 2.8mmol/l or 16.7mmol/l glucose, in presence of KCl (30mmol/l) plus diazoxide (250µmol/l) as described by Henquin (31 (33) , implementing the "Sine + DC" feature of the Lock-in module (40mV peak-to-peak and a frequency of 500Hz for depolarization-evoked exocytosis) in whole-cell configuration. Recordings were conducted using EPC10 patch clamp amplifier, Pulse and X-Chart softwares (HEKA Electronik, Lambrecht, Germany). Exocytic events were elicited by a train of eight 500-ms depolarization pulses (1-Hz stimulation frequency) from -70 to 0mV. For Ca 2+ infusion experiments, a 40mV peak-to-peak 800Hz sine wave about the holding potential (-70mV) was applied (32 16 .7mmol/l glucose stimulated a biphasic secretory pattern in both groups of islets (Fig.1A) .
Results
GLP-1 stimulation normalizes insulin secretory deficiencies in islets from
However, Munc13-1 +/-islets displayed a markedly lower level of insulin secretion in both phases compared to Munc13-1 +/+ islets, culminating in 37% reduction in F-PIS (3.42±0.33 vs 2.17±0.32), and 45% reduction in S-PIS (10.51±1.12 vs 5.79±0.56) as quantified by area-under-the-curve (AUC) analysis ( Fig.1A-B) .
Remarkably, subsequent addition of 10nmol/l of GLP-1 potentiated S-PIS in Munc13-1 +/-islets to the same extent as Munc13-1 +/+ islets (Fig.1A) . In a second protocol, GLP-1 potentiated F-PIS and S-PIS in Munc13-1 +/+ and Munc13-1 +/-islets to the same extent (Fig.1C) .
To more rigorously determine which phase(s) of insulin secretion GLP-1 was rescued, we used a wellestablished protocol (31) (Fig.3D) .
Similarly, the normalized exocytosis in Munc13-1 +/-β-cells is not due to altered whole-cell currents as explained above. The full rescue of RRP in Munc13-1 +/-β-cells by maximal cAMP stimulation is commensurate to GLP-1-potentiated F-PIS in the Munc13-1 +/-islet perifusion study (Fig.1) Any of these secretory components could have been acted upon by cAMP to rescue exocytosis (in Fig. 2 ) in a manner independent of the residual Munc13-1. To negate the contributions from these confounding possibilities, we 'bypassed' the plasma membrane Ca 2+ channel by infusing into β-cells a constant stimulatory concentration of Ca 2+ (1.5µmol/l) to induce Ca 2+ -evoked exocytosis (Fig.3E) . Analysis of the rate of change of C m (cAMP free) at 60-120s period, which approximates the refilling rate of a releasable pool of vesicles, showed a reduction of 41% in Munc13-1 +/-β-cells (3.32±0.22 fF *S -1 vs 5.67±0.51 fF *S -1 in Munc13-1 +/+ β-cells, Fig. 3F ). This magnitude of reduction is similar to that observed with the serial depolarization (54%) study (Fig.3A-D) . However, when we calculated the rate of change of C m during the first 30s, which approximates the RRP size, we saw a reduction of 27% in Munc13-1 +/-β-cells (6.70±0.53 fF *S -1 vs 9.24±0.85 fF *S -1 in Munc13-1 +/+ β-cells, Fig. 3F ). This reduction is milder than that seen when exocytosis was induced by serial depolarization (52%) (Fig.3A-D (Fig.4A) . These cAMP receptors are therefore equally intact in both Munc13-1 +/+ and Munc13-1 +/-β-cells for cAMP to exert its full actions.
We proceeded to examine the independent actions of Epac signaling. We performed intracellular dialysis of 10µmol/l 8-pCPT-2'-O-Me-cAMP, a selective agonist for Epac but not PKA (17) .
While 8-CPT enhanced depolarization-evoked exocytosis (cAMP-free) in both groups of β-cells (Fig.4B-C) , Epac-potentiated exocytosis was less than that potentiated by maximal cAMP stimulation (Fig.3A-D 
+/-and Munc13-1 +/+ β-cells (Fig.5A-B Fig.5C ). These patterns are rather similar to those effected by maximal cAMP activation (Fig.3) . As control for Rim2PDZ, 1µmol/l GSTRim2PDZ(AAA), a mutant which cannot bind Epac2(28), did not affect cAMPmediated potentiation of exocytosis (Supplemental To confirm the inhibitory effects of GSTRim2PDZ were indeed attributable to blockade of Epac signaling, we showed that GST-Rim2PDZ completely inhibited the potentiating effects of 8CPT (Fig.5D-F) .
Since the PKA signaling pathway was discriminated only indirectly by inhibiting Epac signaling in Fig.5 , we examined direct PKA activation by dialyzing 100µmol/l N 6 -Bnz-cAMP, an agonist selective for PKA but not Epac (34) . N 6 -Bnz-cAMP stimulation increased the size of RRP (Σ∆Cm 1st-2ndpulse ) in Munc13-1 +/-β-cells (7.18±0.51 fF/pF) to a similar extent as Munc13-1 +/+ β-cells (8.20±0.72 fF/pF) (Fig.6A-C Fig.6A-C) . These results suggest that PKA activation alone has a tendency to overcome most of the exocytotic defects caused by Munc13-1 deficiency. Nonetheless, maximal PKA-potentiated exocytosis by N 6 -Bnz-cAMP was less than maximal cAMP potentiation (Fig.6C) , consistent with previous reports (28) . When these results are further compared to 8-CPT (from Fig.4) , Epac signaling accounts for some of the cAMP rescue of the exocytotic defects in Munc13-1 +/-β-cells but seems to contribute somewhat less to the cAMP rescue than PKA signaling (Fig.6D) . Nonetheless, it also appears that synergicstic actions of both Epac and PKA signaling are required for full cAMP rescue.
Blockade of Munc13-1-Rim Interaction (omit "PKA pathway") severely impairs cAMP rescue of exocytic defects in Munc13-1 +/-
islet β-cells-If PKA activation tends to account for much of the cAMP-mediated rescue of exocytotic defects in Munc13-1 +/-β-cells, then blockade of PKA signaling should block these potentiating actions of maximal cAMP stimulation. Here, we have used the potent and relatively selective PKA inhibitor H89 (3µmol/l) plus 100µmol/l cAMP, which would leave Epac2 signaling intact. Indeed, in presence of H89, cAMP failed to fully amplify insulin exocytosis in both groups of β-cells (Fig.7A-B) . C m changes were much lower in Munc13-1 +/-β-cells in majority of depolarization pulses (Fig.7A-B) . RRP (Σ∆Cm 1st-2ndpulse ) was reduced by 43% in Munc13-1 +/-β-cells (3.21±0.70 fF/pF vs 5.66±1.27 fF/pF in Munc13-1 +/+ β-cells, Fig.7C ). Refilling of a releasable pool of vesicles (Σ∆Cm 3th-8thpulse ) was similarly impaired by 42% in Munc13-1 +/-β-cells (10.40±0.81 fF/pF vs 17.99±2.14 fF/pF in Munc13-1 +/+ β-cells, Fig.7C ). These results confirm that PKA signaling is a major contributor to cAMP potentiation and rescue of the exocytotic defects in Munc13-1 +/-β-cells. Rim2 has been suggested to mediate PKA-dependent potentiation of insulin secretion (18) . Rim isoforms requires PKAdependent phosphorylation for activation (21) and is believed to interact with Munc13-1 to enhance Munc13-1's exocytic action (24) , but the precise mechanism remains unclear.
We hypothesized that functional interaction of Munc13-1 and Rim was critical for PKA signaling to overcome the Munc13-1 deficiency. We blocked endogenous Rim2-Munc13-1 interaction in β-cells by dialysis of 1µmol/l GST-Munc13-1-Rim-binding domain (RBD) peptide (35) . Here, cAMP rescue of RRP size and refilling of a releasable pool of vesicles in Munc13-1 +/-β-cells were greatly reduced (Fig.8A-B Fig.8C ). These results strongly support a putative role of Munc13-1-Rim interaction in cAMP-mediated rescue of Munc13-1 exocytotic defects.
Discussion
Biphasic insulin secretion is attributed to exocytosis of distinct pools of insulin vesicles, which become severely perturbed in type-2 diabetes(3). GLP-1 mimetics, acting on cAMP-and PKA-signaling pathways, have emerged as promising therapeutic agents in treating type-2 diabetes(4), by normalizing insulin exocytotic defects. However, the molecular substrates and corresponding steps in exocytosis (vesicle priming and refilling) acted upon by GLP-1 remain unclear. In this work, we have gained much insight into the functional interactions of Munc13-1, Epac, and PKA (including Rim), which comprise the priming machinery for vesicle priming and refilling steps of exocytosis. We have used Munc13-1 haplodeficient mouse islets which exhibit defective biphasic insulin secretion mimicking type-2 diabetes, and whose β-cells exhibit major defects in priming and refilling steps in exocytosis. We examined how these defects caused by Munc13-1 deficiency are selectively rescued by agents acting on distinct cAMP and PKA signaling pathways. Below, we discuss our major findings.
First, we characterized the kinetics of insulin secretion and exocytosis of adult haplodeficient Munc13-1 +/-islets. Islet perifusion studies showed that Munc13-1 +/-islets had severe reduction in F-PISand S-PIS. Consistently, C m measurements revealed severe impairment in the size of RRP and rate of refilling of a releasable pool of vesicles. Using homozygous Munc13-1 -/-knockout mouse islets, Kang et al. showed nearly abolished S-PIS and severely reduced F-PIS (12) . Their C m measurements showed Munc13-1 -/-β-cells to exhibit severe reduction in rate of refilling of a releasable pool of vesicles, but surprisingly, the size of RRP was normal. Of note, in Kang's study, β-cells examined were from perinatal mice, as homozygous Munc13-1 -/-mice die shortly after birth (7) . The size of RRP of insulin vesicles in Munc13-1 -/-mice could be larger initially which may then undergo normal progressive reduction during development. Alternatively, progressive reduction of RRP and F-PIS could have been induced by the diabetic state as adult Munc13 +/-mice are glucose-intolerant (11) . A more prolonged period of Munc13-1 deficiency in adult Munc13 +/-mice could lead to reduced tightness of coupling between Ca 2+ channels and insulin vesicles, resulting in less efficient excitosome complex to effect exocytosis (36) .
Second, GLP-1 stimulation normalized biphasic insulin secretory defects caused by Munc13-1 deficiency. Consistently, examination of kinetics of exocytosis showed that maximal cAMP stimulation completely restored the size of RRP, and almost completely recovered the rate of refilling of a releasable pool of vesicles. The restoration was not due to alteration in Ca 2+ entry through voltage-gated Ca 2+ channels, which we previously showed to be normal(11), but was in part due to rescue of impaired sensitivity to a Ca 2+ trigger as demonstrated in the Ca 2+ infusion experiments. The rescue of refilling of a releasable pool of vesicles was somewhat less efficient than the complete rescue of S-PIS as serial depolarization is 'supraphysiologic' compared to physiologic GSIS.
Nonetheless, such an acute supraphysiologic stimulation may simulate the prolonged and high demand on pancreatic islets imposed by diabetes. Islet levels cAMP receptors-Epac and PKA substrate Rim2, as well as cAMP production were normal in Munc13 +/-mice, indicating that GLP-1 could activate these cAMP receptors to bypass Munc13-1 deficiency or interact with residual Munc13-1 proteins to promote insulin exocytosis. Below, we discussed the independent contributions of Epac and PKA signaling.
Third, Epac activation partially normalized the defects in priming and refilling of a releasable pool of vesicles caused by Munc13-1 deficiency. Epac2 and Rim2 interaction is essential for GLP-1-enhanced insulin secretion (18) . Epac2/Rim2 complex was postulated to serve as a scaffold to bind and orchestrate additional exocytic proteins, including not only Munc13-1(24;27) and SNARE proteins, but also other proteins involved in exocytosis, including Piccolo (Ca 2+ sensor of this complex), L-type Ca 2+ channel α-subunit, and nucleotide-binding fold of sulfonylurea receptor 1 (SUR1) (18) . Epac activation through SUR1 inhibits K ATP channels(30), and also enhances Cl -influx from insulin vesicles(37), leading to enhanced insulin exocytosis, and which was abolished in SUR1 null mice (29) . Ca 2+ -induce-Ca 2+ release could be amplified by Epac activation (17) . Epac2 therefore integrates ATP, cAMP, and Ca 2+ signals in pancreatic β-cells to facilitate stimulus-exocytosis coupling.
Our results showed that Epac signaling contributes to but is insufficient to account for the full cAMP rescue of exocytic defects in Munc13-1 +/-β-cells. Fourth, PKA activation is a major contributor to cAMP rescue of exocytic defects caused by Munc13-1 deficiency and is in part mediated via Rim2-Munc13-1 interaction. We show that PKA activation fully amplified the size of RRP of insulin vesicles to the same extent as maximal cAMP stimulation, and partially accelerated refilling of a releasable pool of vesicles. PKA-catalyzed protein phosphorylation is known to potentiate insulin secretion but the precise molecular substrates remain largely unknown (18) . Rim proteins are major phosphorylation targets of PKA and can directly bind Munc13-1 (7;21) . We here demonstrated that Rim2-Munc13-1 interaction indeed was critical for the rescue by PKA. Rim binds Munc13-1 even when it is not PKA-phosphorylated, and disruption of Rim-Munc13-1 binding reduces fusion-competent synaptic vesicles mimicking Munc13-1 knockout neurons (25) . Although Munc13-1's Nterminal Rim-binding L-region does not exert a priming reaction per se (25;38) , this binding is thought to influence indirectly Munc13-1's priming activity by promoting recruitment of Munc13-1 or causing conformational changes in Munc13-1 that affect its priming activity (27) (45), the majority of which are also involved in insulin secretion (46) (47) (48) . Although few studies have attempted to explain the precise functional consequences of PKAcatalyzed phosphorylation of these substrates on insulin and neurotransmitter release (49;50) , much is still unknown and remain to be further studied, including the possibility that they could functionally interact with Munc13-1.
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